Table 1: Sales by Segment 1 Table 2: Sales by Geographic Area 2 Table 3: Sales of Key Products/Franchises 3 - 8 Table 3a: Supplemental Sales Reconciliation 9 Table 4: Condensed Consolidated Statement of Earnings - QTD 10 Table 5: Condensed Consolidated Statement of Earnings - YTD 11 Table 6: Non-GAAP Adjusted Operational Sales Growth - QTD 12 Table 7: Non-GAAP Adjusted Operational Sales Growth - YTD 13 Table 8: Non-GAAP Adjusted Net Earnings 14 Table 9: Non-GAAP IBT by Segment - QTD 15 Table 10: Non-GAAP IBT by Segment - YTD 16 Table 11: Non-GAAP P&L Reconciliation 17 Third Quarter 2022 Other Financial Disclosures Table of Contents -- 1 of 18 -- Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) Percent Change 2022 2021 Total Operations Currency 2022 2021 Total Operations Currency Sales to customers by segment of business Consumer Health (1) U.S. 1,659 $ 1,625 2.1 % 2.1 - 4,903 $ 4,987 (1.7) % (1.7) - International 2,136 2,187 (2.3) 6.7 (9.0) 6,283 6,320 (0.6) 6.0 (6.6) 3,795 3,812 (0.4) 4.7 (5.1) 11,186 11,307 (1.1) 2.6 (3.7) Pharmaceutical (1) U.S. 7,438 7,221 3.0 3.0 - 21,229 20,536 3.4 3.4 - International 5,776 5,661 2.0 16.7 (14.7) 18,171 16,927 7.3 18.5 (11.2) 13,214 12,882 2.6 9.0 (6.4) 39,400 37,463 5.2 10.2 (5.0) Pharmaceutical excluding COVID-19 Vaccine (1,3) U.S. 7,438 6,951 7.0 7.0 - 21,109 20,115 4.9 4.9 - International 5,287 5,429 (2.6) 11.3 (13.9) 16,801 16,582 1.3 11.7 (10.4) 12,725 12,380 2.8 8.9 (6.1) 37,910 36,697 3.3 8.0 (4.7) MedTech (2) U.S. 3,356 3,117 7.7 7.7 - 9,932 9,470 4.9 4.9 - International 3,426 3,527 (2.9) 8.5 (11.4) 10,719 10,731 (0.1) 8.2 (8.3) 6,782 6,644 2.1 8.1 (6.0) 20,651 20,201 2.2 6.6 (4.4) U.S. 12,453 11,963 4.1 4.1 - 36,064 34,993 3.1 3.1 - International 11,338 11,375 (0.3) 12.3 (12.6) 35,173 33,978 3.5 12.9 (9.4) Worldwide 23,791 23,338 1.9 8.1 (6.2) 71,237 68,971 3.3 7.9 (4.6) U.S. 12,453 11,693 6.5 6.5 - 35,944 34,572 4.0 4.0 - International 10,849 11,143 (2.6) 9.5 (12.1) 33,803 33,633 0.5 9.5 (9.0) Worldwide excluding COVID-19 Vaccine (3) 23,302 $ 22,836 2.0 % 8.0 (6.0) 69,747 $ 68,205 2.3 % 6.7 (4.4) Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. (1) Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes. (3) Refer to supplemental sales reconciliation Page 1 of 17 THIRD QUARTER Percent Change NINE MONTHS (2) Previously referred to as Medical Devices -- 2 of 18 -- Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) Percent Change 2022 2021 Total Operations Currency 2022 2021 Total Operations Currency Sales to customers by geographic area U.S. 12,453 $ 11,963 4.1 % 4.1 - 36,064 $ 34,993 3.1 % 3.1 - Europe 5,524 5,587 (1.1) 14.5 (15.6) 17,633 16,669 5.8 18.2 (12.4) Western Hemisphere excluding U.S. 1,562 1,500 4.1 9.1 (5.0) 4,580 4,291 6.7 9.6 (2.9) Asia-Pacific, Africa 4,252 4,288 (0.9) 10.5 (11.4) 12,960 13,018 (0.4) 7.2 (7.6) International 11,338 11,375 (0.3) 12.3 (12.6) 35,173 33,978 3.5 12.9 (9.4) Worldwide 23,791 $ 23,338 1.9 % 8.1 (6.2) 71,237 $ 68,971 3.3 % 7.9 (4.6) Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. Page 2 of 17 THIRD QUARTER Percent Change NINE MONTHS -- 3 of 18 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER NINE MONTHS 2022 2021 Reported Operational (1) Currency 2022 2021 Reported Operational (1) Currency CONSUMER HEALTH SEGMENT (2,3) OTC US 695 $ 686 1.4% 1.4% - 2,028 $ 1,960 3.5% 3.5% - Intl 825 798 3.4% 12.2% -8.8% 2,434 2,223 9.5% 16.3% -6.8% WW 1,519 1,484 2.5% 7.2% -4.7% 4,462 4,183 6.7% 10.3% -3.6% SKIN HEALTH / BEAUTY US 591 569 3.7% 3.7% - 1,764 1,862 -5.3% -5.3% - Intl 535 555 -3.6% 6.2% -9.8% 1,500 1,595 -6.0% 1.5% -7.5% WW 1,126 1,124 0.1% 5.0% -4.9% 3,264 3,457 -5.6% -2.2% -3.4% ORAL CARE US 158 150 5.2% 5.2% - 471 478 -1.5% -1.5% - Intl 217 248 -12.4% -4.3% -8.1% 664 762 -12.8% -7.2% -5.6% WW 375 398 -5.8% -0.7% -5.1% 1,135 1,240 -8.5% -5.0% -3.5% BABY CARE US 91 95 -4.0% -4.0% - 264 288 -8.2% -8.2% - Intl 283 296 -4.5% 3.4% -7.9% 840 879 -4.4% 0.8% -5.2% WW 375 391 -4.3% 1.6% -5.9% 1,105 1,167 -5.4% -1.5% -3.9% WOMEN'S HEALTH US 2 3 -22.0% -22.0% - 9 9 -2.8% -2.8% - Intl 222 229 -2.7% 8.4% -11.1% 674 675 -0.1% 8.0% -8.1% WW 225 232 -3.0% 7.9% -10.9% 684 684 -0.1% 7.8% -7.9% WOUND CARE / OTHER US 122 122 -0.2% -0.2% - 366 390 -6.0% -6.0% - Intl 53 61 -11.4% -7.1% -4.3% 170 186 -8.2% -5.4% -2.8% WW 176 182 -3.9% -2.5% -1.4% 537 575 -6.7% -5.8% -0.9% TOTAL CONSUMER HEALTH US 1,659 1,625 2.1% 2.1% - 4,903 4,987 -1.7% -1.7% - Intl 2,136 2,187 -2.3% 6.7% -9.0% 6,283 6,320 -0.6% 6.0% -6.6% WW 3,795 $ 3,812 -0.4% 4.7% -5.1% 11,186 $ 11,307 -1.1% 2.6% -3.7% See footnotes at end of schedule Page 3 of 17 % Change % Change -- 4 of 18 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER NINE MONTHS PHARMACEUTICAL SEGMENT (2,3) 2022 2021 Reported Operational (1) Currency 2022 2021 Reported Operational (1) Currency IMMUNOLOGY US 2,876 $ 2,771 3.8% 3.8% - 8,230 $ 7,932 3.8% 3.8% - Intl 1,411 1,480 -4.7% 8.9% -13.6% 4,587 4,464 2.8% 12.9% -10.1% WW 4,287 4,250 0.9% 5.6% -4.7% 12,817 12,395 3.4% 7.1% -3.7% REMICADE US 350 480 -27.0% -27.0% - 1,099 1,508 -27.1% -27.1% - US Exports (4) 39 47 -16.9% -16.9% - 163 197 -17.2% -17.2% - Intl 169 234 -27.8% -22.8% -5.0% 606 721 -16.0% -11.9% -4.1% WW 558 761 -26.6% -25.1% -1.5% 1,868 2,426 -23.0% -21.8% -1.2% SIMPONI / SIMPONI ARIA US 298 295 0.9% 0.9% - 886 840 5.4% 5.4% - Intl 248 276 -10.4% 3.0% -13.4% 797 877 -9.2% 0.4% -9.6% WW 545 571 -4.6% 1.9% -6.5% 1,682 1,717 -2.0% 2.9% -4.9% STELARA US 1,655 1,569 5.5% 5.5% - 4,766 4,396 8.4% 8.4% - Intl 794 809 -1.9% 12.9% -14.8% 2,571 2,404 6.9% 18.2% -11.3% WW 2,449 2,378 3.0% 8.0% -5.0% 7,336 6,800 7.9% 11.9% -4.0% TREMFYA US 530 376 40.7% 40.7% - 1,303 975 33.6% 33.6% - Intl 200 161 24.6% 44.5% -19.9% 613 459 33.7% 49.0% -15.3% WW 729 537 35.9% 41.9% -6.0% 1,916 1,434 33.6% 38.5% -4.9% OTHER IMMUNOLOGY US 5 3 * * - 14 15 -3.5% -3.5% - Intl 0 0 * * * 0 3 * * * WW 5 3 * * * 14 18 -19.3% -19.3% 0.0% INFECTIOUS DISEASES US 390 679 -42.7% -42.7% - 1,266 1,635 -22.6% -22.6% - Intl 905 698 29.7% 49.1% -19.4% 2,642 1,758 50.3% 67.1% -16.8% WW 1,295 1,378 -6.0% 3.8% -9.8% 3,908 3,394 15.2% 23.9% -8.7% COVID-19 VACCINE US 0 270 * * - 120 421 -71.5% -71.5% - Intl 489 233 * * * 1,370 346 * * * WW 489 502 -2.7% 13.1% -15.8% 1,490 766 * * * EDURANT / rilpivirine US 9 12 -27.1% -27.1% - 27 31 -14.5% -14.5% - Intl 237 247 -4.2% 9.8% -14.0% 691 733 -5.7% 4.8% -10.5% WW 245 259 -5.2% 8.2% -13.4% 718 764 -6.1% 4.0% -10.1% PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA US 372 380 -2.2% -2.2% - 1,096 1,128 -2.9% -2.9% - Intl 112 137 -17.9% -6.3% -11.6% 354 440 -19.5% -11.2% -8.3% WW 485 517 -6.4% -3.3% -3.1% 1,450 1,568 -7.5% -5.2% -2.3% OTHER INFECTIOUS DISEASES US 10 18 -46.4% -46.4% - 24 55 -57.2% -57.2% - Intl 68 82 -17.1% -10.8% -6.3% 228 240 -5.0% 0.2% -5.2% WW 77 99 -22.4% -17.2% -5.2% 251 295 -14.8% -10.6% -4.2% Page 4 of 17 % Change % Change -- 5 of 18 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER NINE MONTHS 2022 2021 Reported Operational (1) Currency 2022 2021 Reported Operational (1) Currency NEUROSCIENCE US 919 835 10.0% 10.0% - 2,658 2,448 8.6% 8.6% - Intl 763 845 -9.9% 1.8% -11.7% 2,498 2,751 -9.2% -0.6% -8.6% WW 1,681 1,680 0.0% 5.9% -5.9% 5,156 5,199 -0.8% 3.7% -4.5% CONCERTA / Methylphenidate US 41 35 19.3% 19.3% - 114 117 -2.2% -2.2% - Intl 117 122 -4.4% 8.0% -12.4% 362 372 -2.6% 6.5% -9.1% WW 158 157 0.8% 10.5% -9.7% 476 489 -2.5% 4.4% -6.9% INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA US 684 648 5.3% 5.3% - 2,036 1,882 8.1% 8.1% - Intl 348 355 -2.3% 12.2% -14.5% 1,097 1,111 -1.3% 9.4% -10.7% WW 1,031 1,004 2.6% 7.8% -5.2% 3,132 2,994 4.6% 8.6% -4.0% RISPERDAL CONSTA US 67 71 -6.1% -6.1% - 195 210 -7.1% -7.1% - Intl 52 69 -24.2% -11.3% -12.9% 178 242 -26.3% -17.0% -9.3% WW 119 140 -14.9% -8.6% -6.3% 373 452 -17.4% -12.4% -5.0% OTHER NEUROSCIENCE US 127 81 57.2% 57.2% - 313 239 31.1% 31.1% - Intl 246 298 -17.9% -10.0% -7.9% 861 1,026 -16.2% -10.2% -6.0% WW 374 379 -1.9% 4.3% -6.2% 1,174 1,265 -7.3% -2.4% -4.9% ONCOLOGY US 1,812 1,525 18.8% 18.8% - 5,073 4,364 16.2% 16.2% - Intl 2,252 2,140 5.2% 20.9% -15.7% 6,983 6,406 9.0% 20.8% -11.8% WW 4,064 3,665 10.9% 20.0% -9.1% 12,056 10,770 11.9% 19.0% -7.1% DARZALEX US 1,097 841 30.3% 30.3% - 3,071 2,302 33.4% 33.4% - Intl 955 739 29.3% 48.2% -18.9% 2,823 2,076 36.0% 50.8% -14.8% WW 2,052 1,580 29.8% 38.7% -8.9% 5,894 4,378 34.6% 41.6% -7.0% ERLEADA US 254 214 19.1% 19.1% - 693 578 20.0% 20.0% - Intl 235 130 * * * 647 329 * * * WW 490 344 42.2% 51.2% -9.0% 1,340 907 47.7% 54.9% -7.2% IMBRUVICA US 353 413 -14.6% -14.6% - 1,072 1,311 -18.3% -18.3% - Intl 559 654 -14.6% -2.5% -12.1% 1,847 1,996 -7.5% 1.9% -9.4% WW 911 1,066 -14.6% -7.2% -7.4% 2,918 3,307 -11.8% -6.1% -5.7% ZYTIGA / abiraterone acetate US 16 25 -33.1% -33.1% - 54 96 -43.4% -43.4% - Intl 440 523 -15.9% -1.2% -14.7% 1,446 1,653 -12.5% -1.9% -10.6% WW 456 548 -16.7% -2.6% -14.1% 1,500 1,749 -14.2% -4.2% -10.0% OTHER ONCOLOGY US 92 32 * * - 183 76 * * - Intl 64 94 -32.1% -22.6% -9.5% 220 352 -37.5% -31.2% -6.3% WW 155 126 23.1% 30.2% -7.1% 403 428 -5.9% -0.8% -5.1% Page 5 of 17 % Change % Change -- 6 of 18 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER NINE MONTHS 2022 2021 Reported Operational (1) Currency 2022 2021 Reported Operational (1) Currency PULMONARY HYPERTENSION US 604 610 -1.1% -1.1% - 1,736 1,778 -2.4% -2.4% - Intl 247 258 -3.8% 12.5% -16.3% 810 821 -1.3% 10.5% -11.8% WW 852 868 -1.9% 3.0% -4.9% 2,547 2,599 -2.0% 1.7% -3.7% OPSUMIT US 289 299 -3.4% -3.4% - 827 861 -4.0% -4.0% - Intl 152 159 -4.7% 11.6% -16.3% 495 510 -3.0% 8.7% -11.7% WW 441 458 -3.9% 1.8% -5.7% 1,322 1,371 -3.6% 0.7% -4.3% UPTRAVI US 283 265 6.6% 6.6% - 824 792 3.9% 3.9% - Intl 50 44 14.2% 29.5% -15.3% 162 135 20.4% 32.1% -11.7% WW 333 309 7.7% 9.9% -2.2% 986 927 6.3% 8.0% -1.7% OTHER PULMONARY HYPERTENSION US 33 47 -29.5% -29.5% - 86 125 -31.3% -31.3% - Intl 46 54 -15.7% 1.2% -16.9% 154 176 -13.0% -1.0% -12.0% WW 78 101 -22.1% -12.9% -9.2% 239 301 -20.5% -13.5% -7.0% CARDIOVASCULAR / METABOLISM / OTHER US 837 800 4.5% 4.5% - 2,266 2,379 -4.8% -4.8% - Intl 198 241 -17.5% -8.8% -8.7% 651 727 -10.4% -3.8% -6.6% WW 1,034 1,041 -0.6% 1.4% -2.0% 2,916 3,106 -6.1% -4.5% -1.6% XARELTO US 689 636 8.4% 8.4% - 1,806 1,794 0.7% 0.7% - Intl - - - - - - - - - - WW 689 636 8.4% 8.4% - 1,806 1,794 0.7% 0.7% - INVOKANA / INVOKAMET US 49 66 -25.8% -25.8% - 164 249 -34.1% -34.1% - Intl 60 67 -11.0% -2.5% -8.5% 193 194 -0.6% 6.1% -6.7% WW 109 133 -18.4% -14.1% -4.3% 357 443 -19.5% -16.6% -2.9% OTHER US 98 98 -0.1% -0.1% - 295 336 -12.2% -12.2% - Intl 138 173 -20.0% -11.3% -8.7% 458 533 -14.0% -7.3% -6.7% WW 236 271 -12.8% -7.3% -5.5% 753 869 -13.3% -9.2% -4.1% TOTAL PHARMACEUTICAL US 7,438 7,221 3.0% 3.0% - 21,229 20,536 3.4% 3.4% - Intl 5,776 5,661 2.0% 16.7% -14.7% 18,171 16,927 7.3% 18.5% -11.2% WW 13,214 $ 12,882 2.6% 9.0% -6.4% 39,400 $ 37,463 5.2% 10.2% -5.0% See footnotes at end of schedule Page 6 of 17 % Change % Change -- 7 of 18 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER NINE MONTHS MEDTECH SEGMENT (2,3,5) 2022 2021 Reported Operational (1) Currency 2022 2021 Reported Operational (1) Currency INTERVENTIONAL SOLUTIONS US 547 $ 444 23.2% 23.2% - 1,566 1,353 15.7% 15.7% - Intl 513 513 0.0% 13.0% -13.0% 1,636 1,599 2.3% 11.1% -8.8% WW 1,060 957 10.8% 17.7% -6.9% 3,202 2,952 8.5% 13.2% -4.7% ORTHOPAEDICS US 1,309 1,249 4.8% 4.8% - 3,936 3,821 3.0% 3.0% - Intl 785 843 -6.9% 4.6% -11.5% 2,504 2,611 -4.1% 4.3% -8.4% WW 2,095 2,093 0.1% 4.7% -4.6% 6,440 6,433 0.1% 3.5% -3.4% HIPS US 228 209 9.1% 9.1% - 693 651 6.5% 6.5% - Intl 124 146 -15.1% -4.5% -10.6% 437 451 -3.3% 4.6% -7.9% WW 352 355 -0.9% 3.5% -4.4% 1,129 1,102 2.5% 5.7% -3.2% KNEES US 203 184 9.8% 9.8% - 620 579 6.9% 6.9% - Intl 115 131 -12.8% -2.1% -10.7% 386 403 -4.4% 3.7% -8.1% WW 317 316 0.4% 4.9% -4.5% 1,005 983 2.3% 5.6% -3.3% TRAUMA US 473 455 3.8% 3.8% - 1,412 1,352 4.4% 4.4% - Intl 244 260 -6.0% 6.5% -12.5% 749 805 -7.0% 2.3% -9.3% WW 717 715 0.2% 4.8% -4.6% 2,161 2,157 0.2% 3.6% -3.4% SPINE, SPORTS & OTHER US 406 401 1.3% 1.3% - 1,211 1,239 -2.2% -2.2% - Intl 303 306 -1.1% 10.2% -11.3% 933 952 -2.0% 6.1% -8.1% WW 708 706 0.3% 5.2% -4.9% 2,144 2,190 -2.1% 1.4% -3.5% Page 7 of 17 % Change % Change -- 8 of 18 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER NINE MONTHS 2022 2021 Reported Operational (1) Currency 2022 2021 Reported Operational (1) Currency SURGERY US 984 948 3.7% 3.7% - 2,897 2,881 0.5% 0.5% - Intl 1,439 1,457 -1.2% 9.3% -10.5% 4,410 4,418 -0.2% 7.3% -7.5% WW 2,422 2,405 0.7% 7.1% -6.4% 7,306 7,299 0.1% 4.6% -4.5% ADVANCED US 457 440 3.8% 3.8% - 1,328 1,304 1.8% 1.8% - Intl 701 705 -0.4% 9.8% -10.2% 2,132 2,126 0.3% 7.2% -6.9% WW 1,158 1,144 1.2% 7.5% -6.3% 3,460 3,430 0.9% 5.2% -4.3% GENERAL US 527 508 3.6% 3.6% - 1,569 1,577 -0.5% -0.5% - Intl 737 752 -2.0% 8.8% -10.8% 2,277 2,292 -0.6% 7.3% -7.9% WW 1,264 1,261 0.3% 6.7% -6.4% 3,846 3,869 -0.6% 4.1% -4.7% VISION US 517 475 8.8% 8.8% - 1,534 1,414 8.5% 8.5% - Intl 689 714 -3.5% 8.4% -11.9% 2,170 2,103 3.2% 12.9% -9.7% WW 1,206 1,189 1.4% 8.6% -7.2% 3,704 3,517 5.3% 11.1% -5.8% CONTACT LENSES / OTHER US 405 359 12.6% 12.6% - 1,179 1,082 9.0% 9.0% - Intl 503 522 -3.6% 9.5% -13.1% 1,533 1,525 0.5% 11.1% -10.6% WW 908 882 3.0% 10.8% -7.8% 2,712 2,607 4.0% 10.2% -6.2% SURGICAL US 112 117 -3.2% -3.2% - 355 333 6.8% 6.8% - Intl 186 191 -3.3% 5.6% -8.9% 637 577 10.3% 17.6% -7.3% WW 298 308 -3.2% 2.3% -5.5% 992 910 9.0% 13.6% -4.6% TOTAL MEDTECH US 3,356 3,117 7.7% 7.7% - 9,932 9,470 4.9% 4.9% - Intl 3,426 3,527 -2.9% 8.5% -11.4% 10,719 10,731 -0.1% 8.2% -8.3% WW 6,782 $ 6,644 2.1% 8.1% -6.0% 20,651 $ 20,201 2.2% 6.6% -4.4% Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely * Percentage greater than 100% or not meaningful (1) Operational growth excludes the effect of translational currency (2) Unaudited (3) Certain prior year amounts have been reclassified to conform to current year product disclosures (4) Reported as U.S. sales (5) Previously referred to as Medical Devices Page 8 of 17 % Change % Change -- 9 of 18 -- 2022 2021 Total Operations Currency 2022 2021 Total Operations Currency Pharmaceutical U.S. 7,438 $ 7,221 3.0 % 3.0 - 21,229 $ 20,536 3.4 % 3.4 - International 5,776 5,661 2.0 16.7 (14.7) 18,171 16,927 7.3 18.5 (11.2) Worldwide 13,214 12,882 2.6 9.0 (6.4) 39,400 37,463 5.2 10.2 (5.0) COVID-19 Vaccine U.S. 0 270 * * - 120 421 (71.5) (71.5) - International 489 233 * * * 1,370 346 * * * Worldwide 489 502 (2.7) 13.1 (15.8) 1,490 766 * * * Pharmaceutical excluding COVID-19 Vaccine U.S. 7,438 6,951 7.0 7.0 - 21,109 20,115 4.9 4.9 - International 5,287 5,429 (2.6) 11.3 (13.9) 16,801 16,582 1.3 11.7 (10.4) Worldwide 12,725 12,380 2.8 8.9 (6.1) 37,910 36,697 3.3 8.0 (4.7) Worldwide U.S. 12,453 11,963 4.1 4.1 - 36,064 34,993 3.1 3.1 - International 11,338 11,375 (0.3) 12.3 (12.6) 35,173 33,978 3.5 12.9 (9.4) Worldwide 23,791 23,338 1.9 8.1 (6.2) 71,237 68,971 3.3 7.9 (4.6) COVID-19 Vaccine U.S. 0 270 * * - 120 421 (71.5) (71.5) - International 489 233 * * * 1,370 346 * * * Worldwide 489 502 (2.7) 13.1 (15.8) 1,490 766 * * * Worldwide U.S. 12,453 11,693 6.5 6.5 - 35,944 34,572 4.0 4.0 - International 10,849 11,143 (2.6) 9.5 (12.1) 33,803 33,633 0.5 9.5 (9.0) Worldwide excluding COVID-19 Vaccine 23,302 $ 22,836 2.0 % 8.0 (6.0) 69,747 $ 68,205 2.3 % 6.7 (4.4) Note: Columns and rows within tables may not add due to rounding * Percentage greater than 100% or not meaningful Page 9 of 17 Supplemental Sales Reconciliation (Unaudited) (Dollars in Millions) THIRD QUARTER NINE MONTHS Percent Change Percent Change -- 10 of 18 -- Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers 23,791 $ 100.0 23,338 $ 100.0 1.9 Cost of products sold 7,807 32.8 7,250 31.1 7.7 Gross Profit 15,984 67.2 16,088 68.9 (0.6) Selling, marketing and administrative expenses 6,089 25.6 6,000 25.7 1.5 Research and development expense 3,597 15.1 3,422 14.7 5.1 In-process research and development - - 900 3.9 Interest (income) expense, net (99) (0.4) 7 0.0 Other (income) expense, net 493 2.1 1,850 7.9 Restructuring 82 0.3 60 0.2 Earnings before provision for taxes on income 5,822 24.5 3,849 16.5 51.3 Provision for taxes on income 1,364 5.8 182 0.8 649.5 Net earnings 4,458 $ 18.7 3,667 $ 15.7 21.6 Net earnings per share (Diluted) 1.68 $ 1.37 $ 22.6 Average shares outstanding (Diluted) 2,661.3 2,674.9 Effective tax rate 23.4 % 4.7 % Adjusted earnings before provision for taxes and net earnings (1) Earnings before provision for taxes on income 8,073 $ 33.9 8,058 $ 34.5 0.2 Net earnings 6,779 $ 28.5 6,968 $ 29.9 (2.7) Net earnings per share (Diluted) 2.55 $ 2.60 $ (1.9) Effective tax rate 16.0 % 13.5 % (1) See Reconciliation of Non-GAAP Financial Measures. Page 10 of 17 THIRD QUARTER 2022 2021 -- 11 of 18 -- Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers 71,237 $ 100.0 68,971 $ 100.0 3.3 Cost of products sold 23,324 32.7 21,900 31.8 6.5 Gross Profit 47,913 67.3 47,071 68.2 1.8 Selling, marketing and administrative expenses 18,253 25.7 17,505 25.4 4.3 Research and development expense 10,762 15.1 9,994 14.5 7.7 In-process research and development 610 0.9 900 1.3 Interest (income) expense, net (137) (0.2) 83 0.1 Other (income) expense, net 664 0.9 480 0.7 Restructuring 237 0.3 169 0.2 Earnings before provision for taxes on income 17,524 24.6 17,940 26.0 (2.3) Provision for taxes on income 3,103 4.4 1,798 2.6 72.6 Net earnings 14,421 $ 20.2 16,142 $ 23.4 (10.7) Net earnings per share (Diluted) 5.41 $ 6.04 $ (10.4) Average shares outstanding (Diluted) 2,667.5 2,674.6 Effective tax rate 17.7 % 10.0 % Adjusted earnings before provision for taxes and net earnings (1) Earnings before provision for taxes on income 24,462 $ 34.3 24,125 $ 35.0 1.4 Net earnings 20,820 $ 29.2 20,517 $ 29.7 1.5 Net earnings per share (Diluted) 7.81 $ 7.67 $ 1.8 Effective tax rate 14.9 % 15.0 % (1) See Reconciliation of Non-GAAP Financial Measures. Page 11 of 17 NINE MONTHS 2022 2021 -- 12 of 18 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Consumer Health Pharmaceutical MedTech Total WW As Reported (0.4)% 2.6% 2.1% 1.9% U.S. 2.1% 3.0% 7.7% 4.1% International (2.3)% 2.0% (2.9)% (0.3)% WW Currency (5.1) (6.4) (6.0) (6.2) U.S. - - - - International (9.0) (14.7) (11.4) (12.6) WW Operational 4.7% 9.0% 8.1% 8.1% U.S. 2.1% 3.0% 7.7% 4.1% International 6.7% 16.7% 8.5% 12.3% All Other Acquisitions and Divestitures 0.1 0.2 0.0 0.1 U.S. 0.2 0.2 (0.2) 0.1 International 0.0 0.1 0.2 0.1 WW Adjusted Operational 4.8% 9.2% 8.1% 8.2% U.S. 2.3% 3.2% 7.5% 4.2% International 6.7% 16.8% 8.7% 12.4% Page 12 of 17 Adjusted Operational Sales Growth THIRD QUARTER 2022 ACTUAL vs. 2021 ACTUAL Segments Note: Percentages are based on actual, non-rounded figures and may not sum. -- 13 of 18 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Consumer Health Pharmaceutical MedTech Total WW As Reported (1.1)% 5.2% 2.2% 3.3% U.S. (1.7)% 3.4% 4.9% 3.1% International (0.6)% 7.3% (0.1)% 3.5% WW Currency (3.7) (5.0) (4.4) (4.6) U.S. - - - - International (6.6) (11.2) (8.3) (9.4) WW Operational 2.6% 10.2% 6.6% 7.9% U.S. (1.7)% 3.4% 4.9% 3.1% International 6.0% 18.5% 8.2% 12.9% All Other Acquisitions and Divestitures 0.5 0.1 0.1 0.2 U.S. 0.2 0.1 (0.2) 0.1 International 0.7 0.1 0.2 0.2 WW Adjusted Operational 3.1% 10.3% 6.7% 8.1% U.S. (1.5)% 3.5% 4.7% 3.2% International 6.7% 18.6% 8.4% 13.1% Page 13 of 17 Adjusted Operational Sales Growth NINE MONTHS 2022 ACTUAL vs. 2021 ACTUAL Segments Note: Percentages are based on actual, non-rounded figures and may not sum. -- 14 of 18 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures (Dollars in Millions Except Per Share Data) 2022 2021 2022 2021 Net Earnings, after tax- as reported $4,458 $3,667 $14,421 $16,142 Pre-tax Adjustments Intangible Asset Amortization expense 1,041 1,159 3,244 3,576 Litigation related 219 2,077 604 2,054 IPR&D - 900 610 900 Restructuring related 123 121 323 333 Acquisition, integration and divestiture related ¹ - 20 - (504) (Gains)/losses on securities 164 (127) 684 (335) Medical Device Regulation 2 78 59 208 161 COVID-19 Vaccine related costs 3 377 - 653 - Consumer Health separation costs 249 - 619 - Other - - (7) - Tax Adjustments Tax impact on special item adjustments 4 (379) (849) (1,085) (1,097) Consumer Health separation tax related costs 361 - 459 - Tax legislation and other tax related 88 (59) 87 (713) Adjusted Net Earnings, after tax $6,779 $6,968 $20,820 $20,517 Average shares outstanding (Diluted) 2,661.3 2,674.9 2,667.5 2,674.6 Adjusted net earnings per share (Diluted) $2.55 $2.60 $7.81 $7.67 Operational adjusted net earnings per share (Diluted) $2.75 $8.25 Notes: 1 2 3 4 Page 14 of 17 Nine Months Ended Acquisition, integration and divestiture related for the nine months of 2021 primarily includes the gain on the divestiture of two Pharmaceutical brands outside of the U.S. European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance which is expected to be completed during 2024. COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's modification of its COVID-19 vaccine research program and manufacturing capacity to levels that meet all customer contractual requirements. The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings. Third Quarter -- 15 of 18 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures 2022 2021 2022 2021 2022 2021 2022 2021 2022 2021 2022 2021 Reported Income Before Tax by Segment $ 809 (577) 4,249 4,200 1,124 423 (111) (197) (249) - 5,822 3,849 % to Sales 21.3% -15.1% 32.2% 32.6% 16.6% 6.4% -0.5% -0.8% -1.0% 0.0% 24.5% 16.5% Intangible asset amortization expense 83 103 698 799 260 257 - - - - 1,041 1,159 In-process research and development - - - 900 - - - - - 900 Litigation related - 1,359 7 756 212 (38) - - - - 219 2,077 Loss/(gain) on securities - 1 177 (135) (13) 7 - - - - 164 (127) Restructuring related 31 36 23 17 69 68 - - - - 123 121 Acquisition, integration and divestiture related - - - 3 - 17 - - - - - 20 Medical Device Regulation - - - - 78 59 - - - - 78 59 COVID-19 Vaccine related costs - - 377 - - - - - - - 377 - Consumer Health separation costs - - - - - - - - 249 - 249 - Other - - - - - - - - - - - - Adjusted Income Before Tax by Segment $ 923 922 5,531 5,640 1,730 1,693 (111) (197) - - 8,073 8,058 % to Sales 24.3% 24.2% 41.9% 43.8% 25.5% 25.5% -0.5% -0.8% 0.0% 0.0% 33.9% 34.5% 1 Prior year income before tax has been reclassified as Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes *Estimated as of 10/18/2022 Page 15 of 17 Q3 QTD - Income Before Tax by Segment* Dollars in Millions Consumer Health Separation Costs Consumer Health1 Pharmaceutical1 MedTech Unallocated Worldwide Total -- 16 of 18 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures 2022 2021 2022 2021 2022 2021 2022 2021 2022 2021 2022 2021 Reported Income Before Tax by Segment $ 2,279 1,131 12,593 13,663 3,742 3,798 (471) (652) (619) - 17,524 17,940 % to Sales 20.4% 10.0% 32.0% 36.5% 18.1% 18.8% -0.7% -0.9% -0.9% 0.0% 24.6% 26.0% Intangible asset amortization expense 277 314 2,194 2,497 773 765 - - - - 3,244 3,576 In-process research and development - - 610 - - 900 - - - - 610 900 Litigation related 78 1,481 43 675 483 (102) - - - - 604 2,054 Loss/(gain) on securities - (19) 673 (249) 11 (67) - - - - 684 (335) Restructuring related 70 91 32 54 221 188 - - - - 323 333 Acquisition, integration and divestiture related - - - (567) - 63 - - - - - (504) Medical Device Regulation - - - - 208 161 - - - - 208 161 COVID-19 Vaccine related costs - - 653 - - - - - - - 653 - Consumer Health separation costs - - - - - - - - 619 - 619 - Other - - - - - - (7) - - - (7) - Adjusted Income Before Tax by Segment $ 2,704 2,998 16,798 16,073 5,438 5,706 (478) (652) - - 24,462 24,125 % to Sales 24.2% 26.5% 42.6% 42.9% 26.3% 28.2% -0.7% -0.9% 0.0% 0.0% 34.3% 35.0% 1 Prior year income before tax has been reclassified as Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes *Estimated as of 10/18/2022 Page 16 of 17 Q3 YTD - Income Before Tax by Segment* Dollars in Millions Consumer Health Separation Costs Consumer Health1 Pharmaceutical1 MedTech Unallocated Worldwide Total -- 17 of 18 -- Third Quarter Third Quarter Oct 2, 2022 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Other Oct 2, 2022 Non-GAAP Cost of products sold 7,807 $ (1,041) (13) (29) (102) - - - - 6,622 Selling, marketing and admin expenses 6,089 (7) (2) 6,080 Research and development expense 3,597 - (42) (80) - 3,475 Other (Income) / Expense 493 - (219) (28) - (164) (195) (247) - - (360) In-process research and development - - - Restructuring 82 (82) - Provision for taxes on income 1,364 164 (7) - 23 - 43 15 96 45 (361) (88) - 1,294 Net Earnings 4,458 877 226 - 100 - 121 63 281 204 361 88 - 6,779 Third Quarter Third Quarter Oct 3, 2021 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Other Oct 3, 2021 Non-GAAP Cost of products sold 7,250 $ (1,133) (18) (22) 6,077 Selling, marketing and admin expenses 6,000 (6) 5,994 Research and development expense 3,422 - (31) 3,391 Other (Income) / Expense 1,850 (26) (2,077) (43) (20) 127 - - - - (189) In-process research and development 900 (900) - Restructuring 60 (60) - Provision for taxes on income 182 165 433 202 22 (6) 22 11 - - - 59 - 1,090 Net Earnings 3,667 994 1,644 698 99 26 (149) 48 - - - (59) - 6,968 Nine Months Nine Months Oct 2, 2022 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Other Oct 2, 2022 Non-GAAP Cost of products sold 23,324 $ (3,232) (46) (76) (296) 19,674 Selling, marketing and admin expenses 18,253 (19) (2) 18,232 Research and development expense 10,762 - (113) (190) 10,459 Other (Income) / Expense 664 (12) (604) (40) - (684) (167) (617) - 7 (1,453) In-process research and development 610 (610) - Restructuring 237 (237) - Provision for taxes on income 3,103 502 (89) 138 60 - 164 39 161 112 (459) (87) (2) 3,642 Net Earnings 14,421 2,742 693 472 263 - 520 169 492 507 459 87 (5) 20,820 Nine Months Nine Months Oct 3, 2021 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Other Oct 3, 2021 Non-GAAP Cost of products sold 21,900 $ (3,550) (65) (59) 18,226 Selling, marketing and admin expenses 17,505 (17) 17,488 Research and development expense 9,994 - (85) 9,909 Other (Income) / Expense 480 (26) (2,054) (99) 504 335 - - - - (860) In-process research and development 900 (900) - Restructuring 169 (169) - Provision for taxes on income 1,798 505 432 202 59 (104) (27) 30 - - - 713 - 3,608 Net Earnings 16,142 3,071 1,622 698 274 (400) (308) 131 - - - (713) - 20,517 (1) 2021 primarily includes gains on the divestitures of two Pharmaceutical brands outside of the United States. Page 17 of 17 Tax legislation and other tax related Consumer Health separation tax related costs In-process research and development Acquisition, integration and divestiture related (1) (Loss)/gain on securities COVID-19 Vaccine Related Costs Consumer Health separation costs Tax legislation and other tax related Consumer Health separation tax related costs In-process research and development Acquisition, integration and divestiture related (Loss)/gain on securities COVID-19 Vaccine Related Costs Consumer Health separation costs Consumer Health separation tax related costs Acquisition, integration and divestiture related Consumer Health separation costs Tax legislation and other tax related Year to Date In-process research and development (Loss)/gain on securities COVID-19 Vaccine Related Costs Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Quarter to Date Consumer Health separation tax related costs Acquisition, integration and divestiture related Consumer Health separation costs Tax legislation and other tax related In-process research and development (Loss)/gain on securities COVID-19 Vaccine Related Costs -- 18 of 18 --